Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04036500
Other study ID # PRO00035015
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date September 23, 2019
Est. completion date July 13, 2020

Study information

Verified date August 2020
Source Medical College of Wisconsin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Blogs, word-of-mouth, and small studies from the 1990s in the premature ovarian insufficiency and menopause populations have suggested sublingual or transdermal estradiol may be safer and/or more effective than an oral formulation. Sublingual administration entails holding the estrogen tablet under the tongue and allowing it to dissolve, where its absorption is enhanced by the rich vascularization under the tongue. According to Price et al., sublingual administration results in rapid absorption with significantly higher estradiol levels than does comparable oral dosing. This is likely because sublingual administration will bypass metabolism by the intestines and liver. The transdermal route, which also bypasses first-pass metabolism, is not associated with an increased venous thromboembolic risk nor a significant increase in plasma triglycerides or HDL-cholesterol levels. As such, transdermal estrogen is often preferred over oral formulations, although it is relatively expensive and not accessible to many transgender women. Conversely, sublingual administration of estrogen tablets is widely available and could be a cost-effective alternative to transdermal estrogen. However, there are no well-conducted studies that have evaluated the safety and efficacy of sublingual estrogen therapy in the transgender population. This pilot study will elucidate how estrogen levels in the blood change following sublingual versus oral administration of estradiol in transgender women. This data may be used later to design larger studies on safety and efficacy.

Additionally, analyzing a dosage method that patients themselves have tried independently and found effective is also important. This approach incorporates intelligence from the transgender community into our research, creating new knowledge that is supported by data but is founded in existing community insights. Thus, the outcomes of this research have the potential to integrate patient input while also aiding in the development of safety recommendations, with the goal of better caring for our transgender patients.

Primary aim. To establish the pharmacokinetics of sublingual estradiol versus oral estradiol in transgender women.


Description:

Patient will plan on being in the Adult Translational Research Unit (A-TRU) for 8 hours. They will be assigned to a suite. They will get 7 blood draws at hours 0,1,2,3,4,6,8 and vitals at the beginning of the visit. Vitals will include height, weight, blood pressure, respiration rate, and pulse. Subject is able to eat while in the A-TRU. Day 1 patient will take estradiol 1 mg ORALLY after time 0 blood draw. The medication will be given by registered nurse. A wash-out period of at least one week will allow for complete clearance of the exogenous oral estradiol before testing the pharmacokinetics of sublingual estradiol on the same ten patients in the same manner. Subject cannot take any hormone replacement therapy between their research appointments. On day 2, subject will take estradiol 1 mg SUBLINGUALLY after time 0 blood draw, supervised by a research team member to ensure proper dissolution. Blood will be drawn at hours 0,1,2,3,4,6,8 as on day 1.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date July 13, 2020
Est. primary completion date July 13, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Transgender male-to-female

- Naive to hormone therapy

- English speaker

- 18 years of age or older

Exclusion Criteria:

- History of hormone replacement therapy

- Orchiectomy

- Needle phobia

- Serious bleeding condition

- Active deep vein thrombosis, pulmonary embolism or history of these conditions

- Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction)

- Liver dysfunction or disease

- History of breast cancer

- Known sensitivity or allergy to any components of the medications used

- Taking potent CYP3A4 inhibitors or inducers, as determined by team pharmacist

- Taking a medication that may cause additional physical or mental harm if stopped

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Estradiol Tablets
Patients will be given estradiol: 1 mg oral or 1 mg sublingual.

Locations

Country Name City State
United States Froedtert Hospital Milwaukee Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum serum concentration of estradiol 8 hours
Primary Half-life of estradiol 8 hours
Primary Area under the serum concentration versus time curve 8 hours
Primary Oral clearance of estradiol 8 hours
Primary Ratio of estrone to estradiol 8 hours
See also
  Status Clinical Trial Phase
Terminated NCT04534881 - Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen Phase 2
Recruiting NCT05469204 - Effect of Estrogen Treatment on Drug Metabolism and Transport
Not yet recruiting NCT05337865 - Transgender Observational Performance
Completed NCT04448418 - The Impact of COVID-19 Outbreak on Trans-population's Health in Italy
Active, not recruiting NCT05116293 - Effect of Testosterone Treatment on Drug Metabolism and Transport
Recruiting NCT05166083 - Investigation of the Perceptual and Acoustic Voice in Trans Man
Not yet recruiting NCT05927350 - Research Participation With Transgender and Gender-Diverse Youth
Recruiting NCT04515472 - Effect of Gender Affirming Hormone Therapy on Glucose Metabolism Early Phase 1
Not yet recruiting NCT06177600 - TransHealthGUIDE: Transforming Health for Gender-Diverse Youth N/A
Completed NCT03864913 - Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents Early Phase 1
Recruiting NCT05924217 - Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France
Completed NCT05187442 - The Experiences of Erotic and Sexual Risk of Transgender Men: Exploratory Research Design
Completed NCT03120936 - The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community Phase 4
Recruiting NCT04478760 - Trans & Non-binary Reference Intervals While on Hormone Therapy Study